Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases
Application of Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases
1 other identifier
interventional
170
1 country
1
Brief Summary
The goal of this clinical trial is to observe the role of PRF in treating ophthalmic diseases.The efficacy and safety of PRF were validated for four ophthalmic conditions: macular hole, pterygium, corneal ulcer, and patients undergoing trabeculectomy for glaucoma. The main question aims to answer is PRF's effectiveness in ocular surface and fundus diseases. Participants will be divided into 2 groups, the experimental group will be treated with PRF and the control group will be treated with conventional surgery, with a 12-month postoperative follow-up to determine the role of PRF on wound healing in ophthalmic diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2023
CompletedFirst Submitted
Initial submission to the registry
December 11, 2023
CompletedFirst Posted
Study publicly available on registry
January 11, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedJanuary 12, 2024
January 1, 2024
2.5 years
December 11, 2023
January 11, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Whether the macular hole is closed in participants with macular hole(Unit: yes/no)
Using optical coherence tomography（OCT ）to see if the macular hole is healing to compare the healing rate between the PRF membrane filling group and the ILM peeling group.
Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
Whether the wound heals completely after pterygium excision in participants with pterygium(Unit: yes/no)
Observation of the anterior segment of the eye using a slit lamp to determine whether the wound is healed after pterygium excision and to compare the healing rate between the PRF membrane-covered group and the autologous conjunctival-covered group.
Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
IOP in participants undergoing trabeculectomy for glaucoma(Unit: mmHg)
Measurement of IOP using an IOP meter to compare the effect of IOP reduction in glaucoma treatment in the PRF membrane group and the amniotic membrane group.
Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
Whether the corneal ulcer is healing in participants with corneal ulcer(Unit: yes/no)
The investigators use a slit lamp to examine the anterior segment of the eye to assess the corneal wound healing rate. The PRF membrane-covered group is compared to the control group.
Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
Secondary Outcomes (4)
Best-corrected visual acuity (BCVA) in participants with macular hole(Unit: logMAR)
Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
Occurrence of complications in participants with pterygium(Unit: rate)
Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
Degree of tissue scarification in participants undergoing trabeculectomy for glaucoma(Unit: mild, moderate, severe)
Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
Occurrence of complications in participants with corneal ulcer(Unit: rate)
Pre-operation, and at 1 week, 1 month, 3 months, and 6 months post-operation.
Study Arms (8)
PRF membrane in macular hole
EXPERIMENTALTo observe the healing and visual recovery of a macular hole, the macular hole was filled with a PRF membrane. Before the participant went into the operating theatre, a blood sample was taken from the anterior elbow vein using a 5 ml tube without anticoagulants. The middle layer of blood after centrifugation was PRF. After retrobulbar anesthesia and removal of the posterior vitreous cortex. In the PRF group, PRF membrane was utilized to fill the macular hole after the ILM was peeled. Then the eyeball was filled with sterile air after adequate air-liquid exchange. At the end of the operation, tobramycin dexamethasone ophthalmic ointment was applied to the operated eye with pressure, and the participant was instructed to maintain a prone position for 7 days after the operation.
Internal limmiting membrane(ILM) peeling in macular hole
ACTIVE COMPARATORAfter retrobulbar anesthesia and removal of the posterior vitreous cortex, the control group underwent the procedure of peeling the ILM. The ILM was completely removed from the retina. Then the eyeballs were filled with sterile air after adequate air-liquid exchange. At the end of the operation, tobramycin dexamethasone ophthalmic ointment was applied to the operated eye with pressure, and the participant was instructed to maintain a prone position for 7 days after the operation.
PRF membrane transplantation in pterygium
EXPERIMENTALFollowing the removal of the pterygium, the prepared PRF was cut to match the size of the exposed scleral surface. It was then placed on the sclera and secured to the surrounding conjunctiva using 3-7 interrupted sutures of 10-0 nylon thread. This was done to ensure that the PRF implant was perfectly aligned with the conjunctiva.
Autologous conjunctival transplantation in pterygium
ACTIVE COMPARATORAfter the pterygium removal surgery, to restore the eye, participants need to undergo a corneal limbal stem cell transplant. The transplanted stem cells should be the same size as the exposed scleral surface above the temporal part of the eye. When transferring the transplant, ensured that the corneal edge of the grafted conjunctival flap was positioned opposite to the cornea. Closed the flap to the peripheral conjunctiva with 3-7 interrupted sutures using 10-0 nylon thread. Fixed the conjunctival flap to the surrounding conjunctiva with sutures, and covered the sclera with the surrounding bulbar conjunctiva.
PRF membrane transplantation in trabeculectomy for glaucoma
EXPERIMENTALThe surgical procedure involved the creation of a scleral flap and conjunctiva in the usual manner. The subflap tissue was rinsed with balanced saline and then a small piece of tissue (measuring 1.5mm x 2mm) was removed from the inferior trabecular tissue of the scleral flap. In the corresponding position, peripheral iris excision was performed and the iris was rinsed to remove lost pigment in the vicinity of the incision. Once the orientation was verified, the PRF membrane was placed under the scleral flap.
Amniotic membrane in trabeculectomy for glaucoma
ACTIVE COMPARATORThe surgical procedure began with creating the scleral flap and conjunctiva in the usual manner. The sub flap tissue was then rinsed with balanced saline, and a piece of tissue measuring 1.5mm x 2mm was excised from the inferior trabecular tissue of the scleral flap. Next, peripheral iris excision was performed in the corresponding position and the iris was rinsed to remove pigment in the vicinity of the incision. To control the tension of the sutures, the amniotic membrane was placed under the scleral flap, followed by meticulous suturing of the conjunctival flap.
PRF membrane transplantation in corneal ulcer
EXPERIMENTALThe necrotic tissue of the corneal ulcer was cleared to expose the local fresh tissue, and the PRF group prepared PRF membrane and covered the surface of the test eye, and the autologous PRF membrane was continuously sutured to the corresponding surrounding tissues using 10-0 absorbable sutures so that the PRF membrane covered the entire portion of the lesion and was able to be anchored to it.
Amniotic membrane in corneal ulcer
ACTIVE COMPARATORThe necrotic tissue of the corneal ulcer was removed to reveal the fresh tissue in the area. After that, the excess amniotic membrane was carefully extracted and placed over the affected eye's surface. The membrane was then attached securely to the surrounding tissue using 10-0 absorbable sutures, covering the entire lesion and holding it in place for proper healing.
Interventions
A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.
The treatment of the macular hole was ILM peeling.
Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.
Used of autologous conjunctiva to cover exposed sclera after pterygium excision
Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.
Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.
After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing
After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing
Eligibility Criteria
You may qualify if:
- Diagnosis of macular hole confirmed by fundus examination;
- Diagnosis of pterygium by slit lamp;
- Patients requiring trabeculectomy for glaucoma;
- Diagnosis of corneal ulcer confirmed by slit lamp.
You may not qualify if:
- Combination of other active ophthalmic diseases, such as acute conjunctivitis and uveitis;
- Previous history of ophthalmic trauma and ophthalmic surgery;
- Recent use of anticoagulant or antiplatelet drugs;
- Combination of serious systemic diseases such as hypertension and diabetes mellitus.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Lei Dulead
Study Sites (1)
Eye Center, Renmin Hospital of Wuhan University
Wuhan, Hubei, 430060, China
Related Publications (3)
Yang N, Xing Y, Zhao Q, Zeng S, Yang J, Du L. Application of platelet-rich fibrin grafts following pterygium excision. Int J Clin Pract. 2021 Oct;75(10):e14560. doi: 10.1111/ijcp.14560. Epub 2021 Jul 5.
PMID: 34155746BACKGROUNDYang N, Zeng S, Yang J, Lu G, Du L. Application of Platelet-Rich Fibrin Transplantation for Large Macular Hole. Curr Eye Res. 2022 May;47(5):770-776. doi: 10.1080/02713683.2022.2029906. Epub 2022 Mar 22.
PMID: 35179414RESULTLu G, Zeng S, Huang R, Du L. Platelet-rich Fibrin Membrane Transplantation for the Treatment of Highly Myopic Macular Hole Retinal Detachment. Ophthalmol Ther. 2024 Sep;13(9):2425-2443. doi: 10.1007/s40123-024-00997-w. Epub 2024 Jul 26.
PMID: 39060701DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lei Du
Renmin Hospital of Wuhan University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- deputy chief physician
Study Record Dates
First Submitted
December 11, 2023
First Posted
January 11, 2024
Study Start
January 1, 2023
Primary Completion
June 30, 2025
Study Completion
December 31, 2025
Last Updated
January 12, 2024
Record last verified: 2024-01
Data Sharing
- IPD Sharing
- Will not share
This is a new technology and the information may be of commercial value to healthcare organisations and pharmaceutical companies. If this data is made public, it may result in other organisations or businesses gaining access to this information, which may affect the organisation's competitive advantage.